At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
Active +1 moredrug
Likely dose
Active 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Placebo-Controlled, Two-Period, Cross-Over Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma
In Brief
A Phase 2 clinical trial evaluating Active and Placebo for Asthma. Completed, enrolled 14 participants across 2 sites.
Detailed Summary
The purpose of this study is to determine whether a single IV dose of N6022 will have a significant bronchoprotective effect, compared with placebo, during methacholine challenge.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedMar 2011
Primary CompletionNov 2011
Study CompletionDec 2011
TodayJul 2026
First PostedMar 16, 2011
Enrollment StartMar 1, 2011
Primary CompletionNov 1, 2011
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.3 years ago
Interventions
Activedrug
A 5 mg single dose given intravenously via syringe pump over 1 minute.
Placebodrug
Same as active